Shi Dan-Dan, Lyu Jian, Xie Yan-Ming, Sun Lin-Xi, Liu Mei-Xia, Zhang Min
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2020 Aug;45(15):3511-3517. doi: 10.19540/j.cnki.cjcmm.20200501.501.
To explore the population characteristics and clinical application characteristics of patients with cerebral hemorrhage treated with Xingnaojing Injection in real world. The model was established by Apriori algorithm, and the general information and medication information of 8 369 patients with cerebral hemorrhage treated with Xingnaojing Injection were analyzed by using Clementine 12.0 in the databases of information systems of 33 class Ⅲ grade A hospitals in China. The results showed that among the 8 369 patients with cerebral hemorrhage treated with Xingnaojing Injection, the median age was 59 years old. And the male to female ratio was about 1.74∶1. Most of them did manual labor(31.26%), and were hospitalized in winter(27.46%), especially during the Cold Dew(5.1%). The majority of the patients were in a stable condition(50.94%), and preferred neurosurgery department(48.82%). 29.03% of patients were hospitalized for 15-28 days, and 42.47% of patients spent 10 000-50 000 Yuan of hospitalization expenses. The single dose of Xingnaojing Injection was 10-20 mL at most(46.03%). And the course of medication was mostly 3 days or less(68.60%). Lidocain was the most frequently used Western medicine in drug combination(5.05%), and Huayu Tongmai Ji was the most frequently used traditional Chinese medicine in drug combination(10.73%). The most frequently used one type of traditional Chinese medicine combined with one type of Western medicine was Huayu Tongmai Ji + Dexamethasone(8.08%). The most frequently used two Western medicines in drug combination were Omeprazole + Dexamethasone(5.07%). Prilosec + Dexamethasone + Lidocaine(3.35%) were three Western drugs with the most frequent combination. When the dosage was 10-20 mL and the number of days of treatment was > 15 days, the largest number of the patients was cured and improved(44.78%, 45.85%). The results showed that cerebral hemorrhage patients treated with Xingnaojing Injection were mostly middle-aged and elderly people, with more males than females. Brain hemorrhage often occurred in winter and spring. Xingnaojing Injectiont was often combined with glucocorticoids, proton pump inhibitors and cardiovascular drugs to prevent cerebral hemorrhage complications. The clinical medication met the guidelines for the treatment of cerebral hemorrhage. Some patients had over-treatment use, which can provide a reference for clinicians in treating cerebral hemorrhage.
探索醒脑静注射液治疗脑出血患者在真实世界中的人群特征及临床应用特点。采用Apriori算法建立模型，运用Clementine 12.0对我国33家三级甲等医院信息系统数据库中8369例使用醒脑静注射液治疗的脑出血患者的一般信息和用药信息进行分析。结果显示，在8369例使用醒脑静注射液治疗的脑出血患者中，年龄中位数为59岁，男女比例约为1.74∶1。多数患者从事体力劳动（31.26%），冬季住院比例高（27.46%），尤其在寒露节气期间（5.1%）。多数患者病情稳定（50.94%），多选择神经外科就诊（48.82%）。29.03%的患者住院15 - 28天，42.47%的患者住院费用为1万 - 5万元。醒脑静注射液单次用量最多为10 - 20 mL（46.03%），用药疗程多为3天及以内（68.60%）。利多卡因是联合用药中最常用的西药（5.05%），化瘀通脉剂是联合用药中最常用的中药（10.73%）。最常用的一种中药与一种西药联合是化瘀通脉剂 + 地塞米松（8.08%）。联合用药中最常用的两种西药是奥美拉唑 + 地塞米松（5.07%）。泮托拉唑 + 地塞米松 + 利多卡因（3.35%）是联合最频繁的三种西药。当用量为10 - 20 mL且治疗天数＞15天时，治愈和好转的患者数量最多（44.78%，45.85%）。结果表明，使用醒脑静注射液治疗的脑出血患者多为中老年人，男性多于女性。脑出血常发生在冬春季节。醒脑静注射液常与糖皮质激素、质子泵抑制剂及心血管药物联合使用以预防脑出血并发症。临床用药符合脑出血治疗指南。部分患者存在过度治疗使用情况，可为临床医生治疗脑出血提供参考。
